# Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.

> **NCT00849160** · PHASE3 · COMPLETED · sponsor: **Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida** · enrollment: 100 (actual)

## Conditions studied

- HIV-1 Infection
- HIV Infections

## Interventions

- **DRUG:** darunavir

## Key facts

- **NCT ID:** NCT00849160
- **Lead sponsor:** Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2011-06
- **Final completion:** 2011-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00849160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00849160, "Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00849160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*